A bivalent live-attenuated influenza vaccine for the control and prevention of H3N8 and H3N2 canine influenza viruses. Issue 34 (3rd August 2017)

• Record Type: Journal Article
• Authors: Rodriguez, Laura; Nogales, Aitor; Murcia, Pablo R.; Parrish, Colin R.; Martínez-Sobrido, Luis
• Is Part Of: Vaccine. Volume 35:Issue 34(2017)
• Page Start: 4374
• Page End: 4381
• Publication Date: 2017-08-03
• Subjects: Influenza A virus (IAV) -- Canine influenza virus (CIV) -- Inactivated influenza vaccine (IIV) -- Live-attenuated influenza vaccine (LAIV) -- Bivalent vaccine -- Reverse genetics -- Temperature sensitive (ts) -- Cold adapted (ca) -- Attenuated (att) -- Protection efficacy; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2017.06.060
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: We have generated a bivalent LAIV against H3N8 and H3N2 CIVs. The bivalent CIV LAIV is safe and protects against WT H3N8 and H3N2 CIVs. The bivalent CIV LAIV induce better protection than a bivalent CIV IIV. This is the first description of a bivalent LAIV for the prevention of CIVs. Abstract: Canine influenza viruses (CIVs) cause a contagious respiratory disease in dogs. CIV subtypes include H3N8, which originated from the transfer of H3N8 equine influenza virus (EIV) to dogs; and the H3N2, which is an avian-origin virus adapted to infect dogs. Only inactivated influenza vaccines (IIVs) are currently available against the different CIV subtypes. However, the efficacy of these CIV IIVs is not optimal and improved vaccines are necessary for the efficient prevention of disease caused by CIVs in dogs. Since live-attenuated influenza vaccines (LAIVs) induce better immunogenicity and protection efficacy than IIVs, we have combined our previously described H3N8 and H3N2 CIV LAIVs to create a bivalent vaccine against both CIV subtypes. Our findings show that, in a mouse model of infection, the bivalent CIV LAIV is safe and able to induce, upon a single intranasal immunization, better protection than that induced by a bivalent CIV IIV against subsequent challenge with H3N8 or H3N2 CIVs. These protection results also correlated with the ability of the bivalent CIV LAIV to induce better humoral immune responses. This is the first description of a bivalent LAIV for the control and prevention of H3N8 and H3N2 CIV infections in dogs.